Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat ...

“I’m not used to taking all this stuff," he told the Pittsburgh Post-Gazette, "I just want to get off all this medication." ...

FDA approves Johnson & Johnson's Varipulse for targeted atrial fibrillation treatment, enhancing precision and safety ...

Irvine: Johnson & Johnson MedTech has announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

Dr. Mehran Attari, a cardiac electrophysiologist with Mercy Health, discusses a new treatment option for atrial fibrillation (AFib): pulse field ablation (PFA). Atrial fibrillation is the most common ...

Growth of the market is driven by the prevalence of atrial fibrillation cases and cardiac disorders, a rise in the number of hypertension patients, growth in the geriatric population, and increasing ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The terms “controlled AFib” and “uncontrolled AFib” describe whether treatment strategies are effectively managing a person’s irregular heart rate. Controlled AFib is when doctors have ...

Boston Scientific ( NYSE: BSX) has agreed to acquire privately held medical technology company, Cortex, Inc.

AtriCure stock rose more than 16% on news of plans to expand into pulsed field ablation, a tech that could potentially better treat AFib.